Adding Anktiva to BCG led to better responses than BCG alone in people with high-risk bladder cancer who had not yet received BCG, the company said.
|Articles|April 17, 2015
Dr. Bishoy Faltas on the Future of Bladder Cancer Therapy
Bishoy M. Faltas, medical fellow at Weill Cornell Medical College, explains how the genomic landscape of bladder cancers has an impact on possible treatments for patients.
Advertisement
Bishoy M. Faltas, medical fellow at Weill Cornell Medical College, explains how the genomic landscape of bladder cancers has an impact on possible treatments for patients.
"We obviously need to identify more biomarkers," he says, which will help researchers and physicians understand the exact genetic make up of each tumor, which can help guide treatment decisions. Clinical trials are now ongoing to help researchers get to that step.
Advertisement
Related to this article
Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
A breast surgeon explains why patients should raise lymphedema with their care team at the start of treatment, and how early detection can make it reversible.
A woman with stage 4 pancreatic cancer shares how a once-daily RAS inhibitor changed her energy, routine and time with family.
Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
Advertisement
Advertisement